These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31264171)

  • 1. Longitudinal cognitive decline in mild cognitive impairment subjects with early amyloid-β neocortical deposition.
    Ciarmiello A; Giovannini E; Riondato M; Giovacchini G; Duce V; Ferrando O; De Biasi M; Passera C; Carabelli E; Mannironi A; Mansi L; Tartaglione A
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2090-2098. PubMed ID: 31264171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a difference in regional read [
    Farrar G; Molinuevo JL; Zanette M
    Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1299-1308. PubMed ID: 30863934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early detection of amyloid load using
    Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M
    Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.
    Ong KT; Villemagne VL; Bahar-Fuchs A; Lamb F; Langdon N; Catafau AM; Stephens AW; Seibyl J; Dinkelborg LM; Reininger CB; Putz B; Rohde B; Masters CL; Rowe CC
    J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):431-6. PubMed ID: 24970906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-Independent Amnestic Mild Cognitive Impairment and Serum Apolipoprotein A1 Levels.
    Choi HJ; Seo EH; Yi D; Sohn BK; Choe YM; Byun MS; Lee JM; Woo JI; Lee DY
    Am J Geriatr Psychiatry; 2016 Feb; 24(2):144-53. PubMed ID: 26238231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Nomogram for Predicting Amyloid PET Positivity in Amnestic Mild Cognitive Impairment.
    Kim SE; Woo S; Kim SW; Chin J; Kim HJ; Lee BI; Park J; Park KW; Kang DY; Noh Y; Ye BS; Yoo HS; Lee JS; Kim Y; Kim SJ; Cho SH; Na DL; Lockhart SN; Jang H; Seo SW
    J Alzheimers Dis; 2018; 66(2):681-691. PubMed ID: 30320571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease.
    Duara R; Loewenstein DA; Shen Q; Barker W; Potter E; Varon D; Heurlin K; Vandenberghe R; Buckley C
    Alzheimers Dement; 2013 May; 9(3):295-301. PubMed ID: 23178035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
    JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying Brain Connectivity Using Network-Based Statistics in Amnestic Mild Cognitive Impairment Stratified by β-Amyloid Positivity.
    Kim JE; Kim SW; Choi M; Seong JK; Lee JH
    Am J Alzheimers Dis Other Demen; 2019 Mar; 34(2):104-111. PubMed ID: 30497273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
    Hatashita S; Wakebe D
    J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
    Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
    Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct Neural Correlates of Executive Function by Amyloid Positivity and Associations with Clinical Progression in Mild Cognitive Impairment.
    Yoon HJ; Kim SG; Kim SH; Choo ILH; Park SH; Seo EH;
    Yonsei Med J; 2019 Oct; 60(10):935-943. PubMed ID: 31538428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Global and Regional Amyloid Burden by 18 F-Florbetaben PET/CT With Cognitive Impairment Profile and Severity.
    Pena Pardo FJ; García Vicente AM; Amo-Salas M; Mondéjar Marín B; Navarro Muñoz S; García Hortelano P; Rueda Medina I; García Pérez E; Padilla-Bermejo A; Poblete García VM; Marsal Alonso C; Soriano Castrejón Á
    Clin Nucl Med; 2022 Nov; 47(11):923-930. PubMed ID: 36215395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting.
    Roberts RO; Aakre JA; Kremers WK; Vassilaki M; Knopman DS; Mielke MM; Alhurani R; Geda YE; Machulda MM; Coloma P; Schauble B; Lowe VJ; Jack CR; Petersen RC
    JAMA Neurol; 2018 Aug; 75(8):970-979. PubMed ID: 29710225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-Year Longitudinal Changes in Tau Accumulation on [
    Oh M; Oh SJ; Lee SJ; Oh JS; Seo SY; Ryu S; Roh JH; Lee JH; Kim JS
    J Nucl Med; 2024 Mar; 65(3):453-461. PubMed ID: 38302152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal Reference Region to Measure Longitudinal Amyloid-β Change with
    Bullich S; Villemagne VL; Catafau AM; Jovalekic A; Koglin N; Rowe CC; De Santi S
    J Nucl Med; 2017 Aug; 58(8):1300-1306. PubMed ID: 28183994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.